GlassScriptPhysician profile
Enoch Kotei
NPI 1205179512
$315.69
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $135.65 | 2019 | |
| Lilly USA, LLC | $54.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.39 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.17 | 2019 | |
| Novo Nordisk INC | $15.58 | 2019 | |
| Boston Scientific Corporation | $15.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.45 | 2019 | |
| Emd Serono, INC. | $12.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Enoch Kotei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.